These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19620810)

  • 21. Moving beyond fluorouracil for colorectal cancer.
    Mayer RJ
    N Engl J Med; 2000 Sep; 343(13):963-4. PubMed ID: 11006373
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
    Messersmith WA; Laheru DA; Senzer NN; Donehower RC; Grouleff P; Rogers T; Kelley SK; Ramies DA; Lum BL; Hidalgo M
    Clin Cancer Res; 2004 Oct; 10(19):6522-7. PubMed ID: 15475439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Progression of adjuvant chemotherapy for colon cancer].
    He YJ; Dong QM; Li YH
    Ai Zheng; 2005 Dec; 24(12):1546-9. PubMed ID: 16351811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A Case of Chemotherapy-Induced Hyperammonemic Encephalopathy in a Patient with Metastatic Colon Cancer].
    Tanaka T; Miwa K; Fukahori M; Yomoda T; Sakaue T; Nagasu S; Ushijima T; Koga H; Torimura T
    Gan To Kagaku Ryoho; 2019 Feb; 46(2):259-262. PubMed ID: 30914529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
    Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
    Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A Case of Esophageal Cancer with Consciousness Disorder Due to Hyperammonemia during FP Treatment].
    Yamasaki Y; Ryotokuji T; Matsui T; Miura T; Chiba T; Hayashi M; Yokosuka T; Noguchi N; Tsunemi A; Iseki H
    Gan To Kagaku Ryoho; 2023 Apr; 50(4):493-495. PubMed ID: 37066465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].
    Sagawa T; Tsuji Y; Takayanagi N; Hirayama Y; Sakamaki S; Chiba H; Iyama S; Oku T; Sato Y; Takahashi M; Takayama T; Niitsu Y
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):537-43. PubMed ID: 12722689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
    Li J; Xu JM; Li J; Zhang XD; Bai Y; Chu YP; Wang YH; Liu DQ; Jin ML; Shen L
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):225-7. PubMed ID: 18756942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
    Van Cutsem E; Labianca R; Bodoky G; Barone C; Aranda E; Nordlinger B; Topham C; Tabernero J; André T; Sobrero AF; Mini E; Greil R; Di Costanzo F; Collette L; Cisar L; Zhang X; Khayat D; Bokemeyer C; Roth AD; Cunningham D
    J Clin Oncol; 2009 Jul; 27(19):3117-25. PubMed ID: 19451425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Considering Recurrence Prevention Regimen for Colorectal Cancer Patients with Hyperammonemia Caused by Chemotherapy Containing 5-Fluorouracil].
    Aomatsu N; Tsujio G; Aomatsu K
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1851-1853. PubMed ID: 38303229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A case of advanced colon cancer with para-aortic lymph node metastasis responding greatly to treatment by adjuvant chemotherapy of low-dose CPT-11 on an outpatient basis].
    Kawasaki M; Fujita M; Shibata J; Tani T
    Gan To Kagaku Ryoho; 2002 Jun; 29(6):949-53. PubMed ID: 12090050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Irinotecan chemotherapy associated with transient dysarthria and aphasia.
    De Marco S; Squilloni E; Vigna L; Bertagnolio MF; Sternberg CN
    Ann Oncol; 2004 Jul; 15(7):1147-8. PubMed ID: 15205214
    [No Abstract]   [Full Text] [Related]  

  • 33. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
    Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
    Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A case of hepatic metastasis from colon cancer successfully treated with 5-FU, levofolinate (l-LV) and low-dose CPT-11].
    Harada O; Kobayashi M; Sasamoto M; Shimaya S
    Gan To Kagaku Ryoho; 2004 Aug; 31(8):1245-7. PubMed ID: 15332552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Severe Encephalopathy, Lactic Acidosis and Hyperammonaemia With FOLFIRI Plus Aflibercept After Two-stage Hepatectomy: A Case Report.
    Hara Y; Miyamoto Y; Hiyoshi Y; Iwatsuki M; Baba Y; Yoshida N; Baba H
    In Vivo; 2019; 33(2):563-565. PubMed ID: 30804142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer].
    Takahari D; Tsuji Y; Tanaka S; Tsushima T; Ohura K; Honda K; Sumiyoshi T; Yoshizaki N; Kondo H
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):207-11. PubMed ID: 17301528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
    Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Lee SS; Lee JS; Kang YK
    Am J Clin Oncol; 2008 Apr; 31(2):151-6. PubMed ID: 18391599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A case of sigmoid colon cancer with lymphangitis carcinomatosa successfully treated with chemotherapies including molecular targeting drugs].
    Sogabe S; Yuki S; Takagi T; Miyazaki T; Takano H; Kawamoto Y; Nakatsumi H; Sasaki T; Iwanaga I; Uehata Y; Asaka M; Komatsu Y
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):535-8. PubMed ID: 20332699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hyperammonemia with Disturbance of Consciousness during 5-FU plus Nedaplatin Therapy for Esophageal Cancer-A Case Report].
    Okada T; Hirakawa T; Morimoto J; Tanaka H; Miyamoto H; Tsujio G; Kurihara S; Matsutani S; Nagashima D; Hirata K; Iwauchi T; Yamagata S; Uchima Y; Takeuchi K
    Gan To Kagaku Ryoho; 2020 Dec; 47(13):1839-1841. PubMed ID: 33468846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.
    Folprecht G; Tabernero J; Köhne CH; Zacharchuk C; Paz-Ares L; Rojo F; Quinn S; Casado E; Salazar R; Abbas R; Lejeune C; Marimón I; Andreu J; Ubbelohde U; Cortes-Funes H; Baselga J
    Clin Cancer Res; 2008 Jan; 14(1):215-23. PubMed ID: 18172273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.